We know development™ Let’s Talk About Yours
We are an integrated CDMO and bioanalytical CRO built for the complexity of modern drug development. We specialize in advanced drug product development, nanomedicine, and bioanalysis – and work with molecules that keep other CDMOs up at night.
Where complexity finds solutions
Your molecule deserves a partner who's already solved this problem.
Small Molecule Development
End-to-end development for small molecules with complex profiles — poorly soluble compounds, highly potent APIs, controlled substances, and challenging physicochemical characteristics. Our scientists know where the problems hide and how to get ahead of them. From first formulation to GMP batch, your program stays in expert hands.
Discuss Your ProgramLarge Molecule Development
Sterile drug product development and manufacturing for biologics and complex parenteral formulations. Our teams are experienced with the sensitivity and precision these molecules demand – from formulation design through aseptic fill-finish and lyophilization. One team that stays with your program.
Discuss Your ProgramNanomedicine Development
Ardena operates one of Europe's broadest nanomedicine platforms – lipid nanoparticles, polymeric nanoparticles, liposomes, nanosuspensions, and beyond. From building block synthesis through GMP production and regulatory submission, we cover the full development arc for nanoparticle-based therapeutics.
Discuss Your ProgramLeadership Team
Our leadership team brings decades of hands-on experience across drug development, formulation, manufacturing, bioanalysis, and global operations — so when your program hits a hard moment, there's someone in the room who has already solved it.
Chief Executive Officer
Jeremie joined Ardena as Chief Executive Officer in 2024. He brings an extensive knowledge of the life sciences and CDMO industry, and a proven track record of success in the biopharma sector, with 20 years of experience building and growing businesses globally, expending into new markets, and leading large-scale transformations in both publicly traded and privately held companies. Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO, and during his tenure there, led the successful acquisition and integration of multiple companies.
Chief Commercial Officer (CCO)
Henny Zijlstra joined Ardena as Chief Commercial Officer in May 2026. She is an accomplished commercial leader in the pharmaceutical and CDMO industry, with a career built on driving growth through strategic business development, brand positioning, and customer engagement.
Chief Financial Officer (CFO)
Ben Ash joined Ardena in 2026 as Chief Financial Officer. He brings more than 20 years of finance leadership experience, predominantly within the pharmaceutical sector.
Chief Scientific Officer
Since 2019, Ariane has overseen Ardena’s drug product activities, spearheading successful integration and transformation at Ardena Pamplona and expanding the company’s capabilities to include sterile services.
Global Head, CDMO
Ian joined Ardena in 2025 as US Managing Director. He has over 30 years of global experience across multiple functions in both the CDMO and Medical device industry. Ian spent 19 years of his career working at GE in Quality, Finance, Supply Chain, Technical services and Commercial operations. He then joined Catalent in 2013 where he was VP of Sales Operations and more recently GM for the Somerset site. He holds degree in Mechanical Engineering and an MBA from Northwestern University – Kellogg School of Management.
Global Head, CRO
Gunnar Flik joined Ardena in 2024 as Division Head of Bioanalytical Services. With over 20 years of experience in drug discovery within biotech and CRO environments, Gunnar brings a wealth of strategic vision and entrepreneurial expertise to his role. He is dedicated to developing comprehensive short- and long-term strategic plans aimed at optimizing efficiency, fostering growth, and enhancing profitability within Ardena’s Bioanalysis division.
Chief Quality Officer
Dipesh Patel joined Ardena in 2025 as Chief Quality Officer. He brings over 25 years of experience in the pharmaceutical industry, having held senior leadership roles across CDMOs, virtual biotech companies, and large-scale manufacturing organizations. With an academic background in Chemistry, Biology, and Toxicology, he has built a strong track record in both Quality and Operations, overseeing a broad range of dosage forms and regulatory frameworks.
Chief People Officer
Paul Edwards joined Ardena in 2026 as Chief People Officer, bringing over 30 years of international Human Resources leadership across complex, science-driven and global organisations. Paul has extensive experience in shaping people strategy to support organisational growth and transformation, most recently serving in senior HR leadership roles at Catalent Pharma Solutions.
Chief Information Officer
Peter Rose joined Ardena in 2025 as Chief Information Officer. He brings over 25 years of Information Technology leadership experience spanning multiple industries, including chemicals and pharmaceuticals. Most recently, he was the global head of IT infrastructure and security at Diversey, a global chemical manufacturer, driving technology-enabled transformation, and leading a successful IT migration of the company into the Solenis Group.
